A Case-Based Discussion of Clinical Problems in the Management of Patients Treated With Ruxolitinib for Myelofibrosis

There is now increasing and extensive experience of the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF), both in clinical trials and in 'real-world' practice. The drug has been shown to be of benefit in intermediate-1 risk patients with symptomatic splenomegaly or other MF-related symptoms, and higher risk disease. This paper aims to utilize several 'real-life' cases to illustrate several strategies that may help to optimize clinical practice.

 Intern Med J

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.